diffuse large B-cell lymphoma

diffuse large B-cell lymphoma
Name	Diffuse large B-cell lymphoma
Field	Hematology, Oncology

diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma is an aggressive neoplasm of mature B lymphocytes. It commonly arises in lymph nodes or extranodal sites and requires rapid histopathologic and molecular assessment to guide therapy. Management typically involves immunochemotherapy and, in specific contexts, radiotherapy, hematopoietic stem cell transplantation, or targeted agents.

Introduction

Diffuse large B-cell lymphoma is a high-grade hematologic malignancy first characterized in modern classifications during revisions by organizations such as the World Health Organization and task forces connected to institutions like National Cancer Institute and European Society for Medical Oncology. Historical descriptions involved investigators affiliated with centers including Mayo Clinic, Memorial Sloan Kettering Cancer Center, and Fred Hutchinson Cancer Research Center. Landmark trials conducted by cooperative groups such as Cancer and Leukemia Group B and Eastern Cooperative Oncology Group established combination regimens that reshaped standards developed at centers including Johns Hopkins Hospital and MD Anderson Cancer Center.

Epidemiology and risk factors

Incidence varies by geography with contributions from population studies by agencies like Centers for Disease Control and Prevention, Office for National Statistics in the United Kingdom, and cancer registries such as Surveillance, Epidemiology, and End Results Program. Risk increases with age and is associated with immunosuppression from conditions managed at institutions such as Massachusetts General Hospital and clinics participating in HIV research including Rwanda Military Hospital collaborations. Viral associations documented by researchers at University of Tokyo and Karolinska Institutet include links to Epstein–Barr virus in specific subtypes and interactions described in cohorts from National Institutes of Health and University College London. Environmental and iatrogenic risks were examined in studies at Harvard Medical School and University of California, San Francisco.

Pathology and molecular characteristics

Morphologic characterization was refined by pathologists at Royal College of Pathologists and classification schemas published under the aegis of World Health Organization. Histology shows large neoplastic B cells with diffuse growth; immunophenotyping commonly demonstrates markers characterized in laboratories at Stanford University and University of Pennsylvania such as CD20, CD19, and variable BCL6, BCL2 expression. Molecular subtypes—germinal center B-cell–like and activated B-cell–like—emerged from gene-expression profiling efforts led by teams at Broad Institute and Dana-Farber Cancer Institute. Recurrent genetic alterations involving MYC, BCL2, and BCL6 have been reported in consortia including The Cancer Genome Atlas and studies from University of Cambridge and Institut Gustave Roussy. High-risk "double-hit" and "triple-hit" genotypes were delineated in collaborations including Brigham and Women's Hospital and Vanderbilt University Medical Center.

Clinical presentation and diagnosis

Patients often present with rapidly enlarging lymphadenopathy; extranodal involvement may include gastrointestinal tract lesions documented by endoscopy teams at Mayo Clinic and Cleveland Clinic. Systemic "B" symptoms were characterized in cohorts from Royal Marsden Hospital and outpatient clinics at Guy's and St Thomas' NHS Foundation Trust. Diagnostic workup uses imaging modalities standardized by protocols from American College of Radiology and laboratories implementing flow cytometry methods developed at Fred Hutchinson Cancer Research Center and University of Michigan. Biopsy interpretation relies on immunohistochemistry panels and molecular assays available at reference centers including Memorial Sloan Kettering Cancer Center and Institut Pasteur.

Staging and prognostic indices

Staging follows principles established by the Ann Arbor staging system and adaptations used in clinical trials by groups such as International Lymphoma Study Group and European Organization for Research and Treatment of Cancer. Prognostication commonly uses the International Prognostic Index developed from multicenter studies involving institutions like Mayo Clinic and Stanford University Hospital. PET-CT imaging for response assessment was validated in trials coordinated by National Comprehensive Cancer Network member centers including Roswell Park Comprehensive Cancer Center and Hospital of the University of Pennsylvania.

Treatment and management

First-line therapy historically evolved from trials at National Institutes of Health and cooperative groups such as SWOG and CALGB; modern regimens commonly include rituximab developed in collaborations involving Genentech and clinical programs at Memorial Sloan Kettering Cancer Center. Standard immunochemotherapy combinations (e.g., R-CHOP) reflect contributions from oncologists at MD Anderson Cancer Center and Royal Marsden Hospital. Salvage strategies and autologous stem cell transplantation protocols were refined at Fred Hutchinson Cancer Research Center and City of Hope National Medical Center. Emerging targeted therapies and chimeric antigen receptor T-cell approaches originate from translational work at University of Pennsylvania and biotech partners such as Kite Pharma and Juno Therapeutics with regulatory oversight from Food and Drug Administration. Radiotherapy indications are guided by guidelines from American Society for Radiation Oncology and trials from centers including Princess Margaret Cancer Centre.

Outcomes and follow-up care

Survival outcomes reported in population cohorts from Surveillance, Epidemiology, and End Results Program and institutional series at Brigham and Women's Hospital vary by stage and molecular subtype; long-term survivorship care frameworks have been developed by programs at Dana-Farber Cancer Institute and St. Jude Children's Research Hospital. Follow-up includes surveillance imaging protocols influenced by recommendations from National Comprehensive Cancer Network and supportive care addressing late effects studied at Children's Hospital of Philadelphia and Toronto General Hospital. Palliative and survivorship services often coordinate with community organizations such as American Cancer Society and academic centers including Yale Cancer Center.

Category:Lymphoma